2007 Fiscal Year Final Research Report Summary
Identificaiton of tumor associated antigen for pancreatic cancer by SEREX method using sera from patients with advanced disease who underwent immunotherapy
| Project/Area Number |
16390352
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
EGAWA Shinichi Tohoku University, Tohoku University, Associate Professor (00270679)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUKUYAMA Shoji Tohoku University, Hospital, Assistant Professor (10344673)
MOTOI Fuyuhiko Tohoku University, Hospital, Assistant Professor (30343057)
OKADA Takaho Tohoku University, Hospital, Assistant Professor (10375074)
SAKATA Naoaki Tohoku University, Hospital, Assistant Professor (50431565)
|
|---|
| Project Period (FY) |
2004 – 2007
|
| Keywords | pancreatic cancer / SEREX method / cancer antigen / immunotherrapy / dendritic cells / interferon alpha / clinical trial / intralymphatic injection |
|---|
| Research Abstract |
We have performed intra-operative local injection of autologous dendritic cell immediately after intra-operative irradiation of the primary tumor in patients with pancreatic cancer with liver metastases. This preliminary immunotherapy resulted in a partial regression of liver metastases and prolongation of survival in two patients. Using sera of patients with pancreatic cancer in SEREX method, we have identified a novel cancer-testis antigen, KU-CT-1, that was expressed in 30% of this deadly disease. Of 20 patients with pancreatic cancer, 3 patients harbored specific antibody for KU-CT-1. We made tissue miro-array to confirm the frequency of KU-ST-1 and broad-spectrum cancer antigen, such as WT1 and survivin. Although the expression frequency and intensity was not so high, these data suggested the possible targeting immunotherapy against pancreatic cancer. Dendritic cells were induced from the peripheral monocytes from patients with advanced pancreatic cancer and maturated in the presence of IFN-alpha, IFN-gamma, TNF-alpha, IL-1beta and poly I:C. The phenotype and the ability to produce IL-12p70 of these dendritic cells indicated that dendritic cells from advanced disease can be skewed to be cytotoxic. Phase I trial of intralymphatic administration of cytotoxically skewed dendritic cells showed safety and warranted antigen loaded specific immunotherapy for pancreatic cancer.
|
Research Products
(83 results)
